Organigram Holdings Inc (OGI)
1.3300
-0.0600 (-4.32%)
TSX · Last Trade: Apr 6th, 7:30 AM EDT
Detailed Quote
| Previous Close | 1.390 |
|---|---|
| Open | 1.330 |
| Bid | 1.320 |
| Ask | 1.360 |
| Day's Range | 1.280 - 1.360 |
| 52 Week Range | 1.280 - 3.080 |
| Volume | 101,396 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 150,129 |
Chart
News & Press Releases
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram Global”), the cannabis leader in Canada by market share, is pleased to announce its inaugural virtual investor event, the OG Investor Session, taking place on April 10, 2025, at 4pm EST. This online event offers investors a front-row seat to Organigram Global’s next chapter. Attendees will gain valuable insights into the Company’s growth trajectory, engage directly with leadership on key industry trends, and get a behind-the-scenes look at the innovation and strategy driving Organigram Global forward.
By Organigram Global Inc. · Via Business Wire · April 2, 2025
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), Canada’s #1 cannabis company by market share, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Collective Project Limited (“CPL”) for upfront consideration of approximately C$6.2 million, potential milestone payments and potential earnout payments totaling in the aggregate up to C$24M for the twelve-month periods ending September 30, 2025 and September 30, 2026.
By Organigram Holdings Inc. · Via Business Wire · April 1, 2025
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is proud to announce its official rebrand to Organigram Global Inc. (“Organigram Global”), a move that demonstrates the Company’s evolution from an East Coast medical cannabis company into a burgeoning global cannabis leader.
By Organigram Holdings Inc. · Via Business Wire · March 26, 2025
Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI) (NASDAQ: OGI) announced today the results of voting at its annual general and special meeting of shareholders (the “Shareholders”) held virtually on March 24, 2025 (the “Meeting”).
By Organigram Holdings Inc. · Via Business Wire · March 24, 2025
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that on February 28, 2025, the Company closed the third and last of three tranches (the “Third Tranche”) of the previously announced C$124,559,674 follow-on strategic equity investment (the “Investment”) by BT DE Investments Inc. (the “Investor”), a wholly owned subsidiary of British American Tobacco plc (“BAT”). Pursuant to the Third Tranche closing, the Investor acquired 7,562,447 common shares (the “Common Shares”) and 5,330,728 Class A preferred shares (the “Preferred Shares” and together with the Common Shares, the “Shares”) of the Company at a price of C$3.2203 per Share (the “Per Share Price”) for gross proceeds of USD$28,955,918.44 (equal to C$41,519,891)1.
By Organigram Holdings Inc. · Via Business Wire · March 3, 2025
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the first quarter ended December 31, 2024 (“Q1 Fiscal 2025”). The Q1 Fiscal 2025 results include the financial results of Motif Labs Ltd. ("Motif") from December 6, 2024 to December 31, 2024, following the Company's acquisition of Motif.
By Organigram Holdings Inc. · Via Business Wire · February 11, 2025
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2025 ended December 31, 2024, on Tuesday, February 11, 2025, prior to market open.
By Organigram Holdings Inc. · Via Business Wire · February 4, 2025
This earnings release replaces the previously filed earnings release on December 18, 2024 to correct errors in the outstanding share data tables under the heading “CAPITAL STRUCTURE.” No other changes are being made. The Company is also refiling its Management’s Discussion and Analysis for the twelve months ended September 30, 2024 to correct corresponding errors in the outstanding share data table, which corrections will also apply to the MD&A included in the Company’s Annual Report filed on December 18, 2024.
By Organigram Holdings Inc. · Via Business Wire · December 20, 2024
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2024 ended September 30, 2024, on Wednesday, December 18, 2024, prior to market open.
By Organigram Holdings Inc. · Via Business Wire · December 11, 2024
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has announced the acquisition of 100% of Motif Labs Ltd. for CA$90 million ($64 million), comprising of CA$50 million in cash and CA$40 million in Organigram common shares, based on a 30-day trading VWAP of $2.321 on the TSX. An additional CA$10 million contingent consideration is payable in shares, conditional on achieving a share price above $3.2203 within 12 months. The deal is financed through Organigram's cash reserves.
Via Benzinga · December 6, 2024
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Motif Labs Ltd. (“Motif”), for upfront consideration of $90 million, consisting of $50 million in cash and $40 million of Organigram common shares priced based on the 30 day trading VWAP of $2.3210 on the Toronto Stock Exchange (“TSX”). In addition, Motif shareholders will be entitled to receive additional contingent consideration of $10 million payable in Organigram common shares (“Contingent Consideration”), conditional on Organigram achieving a price per share exceeding $3.2203 per share, based on the rolling 30-trading day VWAP on the TSX, within 12 months of the date of the transaction. The Contingent Consideration shall be priced at of $3.22031 per share.
By Organigram Holdings Inc. · Via Business Wire · December 6, 2024
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is thrilled to finally launch Edison Sonics gummies, Organigram’s inaugural product powered by FAST™, the Company’s groundbreaking nanoemulsion technology and a first-to-market innovation.
By Organigram Holdings Inc. · Via Business Wire · November 26, 2024
Cannabis producer Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has closed the second of three tranches of the previously announced CA$124,559,674 ($92.3 million) follow-on strategic equity investment by BT DE Investments Inc., a wholly owned subsidiary of British American Tobacco plc, (NYSE: BTI) on Tuesday. Under the second tranche closing, the investor acquired Organigram's 4,429,740 common shares and 8,463,435 Class A preferred shares at CA$3.2203 per share, for gross proceeds of $30.8 million. The company said on Tuesday that the remaining 12,893,175 shares subscribed for are due to be issued at the per-share price in the final tranche on or around February 28, 2025.
Via Benzinga · September 3, 2024
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that on August 30, 2024, the Company closed the second of three tranches (the “Second Tranche”) of the previously announced C$124,559,674 follow-on strategic equity investment (the “Investment”) by BT DE Investments Inc. (the “Investor”), a wholly owned subsidiary of British American Tobacco plc (“BAT”). Pursuant to the Second Tranche closing, the Investor acquired 4,429,740 common shares (the “Common Shares”) and 8,463,435 Class A preferred shares (the “Preferred Shares” and together with the Common Shares, the “Shares”) of the Company at a price of C$3.2203 per share (the “Per Share Price”) for gross proceeds of USD$30,821,684.69 (equal to C$41,519,891)1. The remaining 12,893,175 Shares subscribed for are due to be issued at the Per Share Price in the final tranche on or around February 28, 2025 (the “Third Tranche”).
By Organigram Holdings Inc. · Via Business Wire · September 3, 2024
In late July, nearly three months after New York Governor Kathy Hochul fired Chris Alexander, the former head of the state's Office of Cannabis Management (OCM), following an internal review, a series of high-level departures made headlines.Connecticut Social Equity Council (SEC), which manages social equity activity for the state's recreational marijuana market, got a new executive director earlier this month. Brandon McGee, who previously worked on Gov. Ned Lamont's reelection in 2022, replaced Ginne-Rae Clay, reported Marijuana Business Daily citing CT Insider.Canopy Growth Corporation and Curaleaf Holdings, Inc. announced CEO shake-ups.
Via Benzinga · August 21, 2024
Cannabis producer Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) announced on Tuesday results for the third quarter ended June 30, 2024, revealing its net revenue increased 25% year-over-year to CA$41.1 million ($29.9 million). Beena Goldenberg, the company's CEO, praised the revenue milestone. "We are pleased to report a strong third quarter, highlighted by a 25% year-over-year increase in net revenue, and a significant improvement in adjusted EBITDA", Goldenberg said. In May, Organigram announced its second international medical cannabis customer in the UK, Avida Medical, a full-service medical cannabis and special medicines manufacturing business. In June, the company announced a strategic investment aimed at expanding its presence within Germany, one of the burgeoning European cannabis markets.
Via Benzinga · August 13, 2024
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the third quarter ended June 30, 2024 (“Q3 Fiscal 2024”).
By Organigram Holdings Inc. · Via Business Wire · August 13, 2024
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), a leading licensed producer of cannabis, is pleased to unveil the preliminary results of its landmark clinical pharmacokinetic (PK) study conducted via the Product Development Collaboration (PDC) on its latest innovation, nanoemulsion technology. This patent-pending technology, branded FAST™ (Fast Acting Soluble Technology), will be the first innovation to be commercialized by Organigram leveraging the output of the PDC*, a “Center of Excellence” established to focus on developing next-generation cannabis products.
By Organigram Holdings Inc. · Via Business Wire · August 7, 2024
Medical cannabis company IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC), with operations in Israel and Germany, will report operational and financial results for the second quarter of 2024 ended June 30, 2024, on Wednesday, Aug. 14, 2024. cbdMD, Inc. (NYSE: YCBD) said it will host a conference call at 4:20 pm Eastern Time, on Wednesday, Aug. 14, 2024, to discuss the company's June 30, 2024 third quarter of fiscal 2024 financial results and business progress. Canadian cannabis producer and distributor Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:4WE) its second quarter 2024 financial results will be released after market close on Monday, Aug. 26, 2024. The company will host a conference call to discuss the results and provide an operational update and recap of achievements on Tuesday, Aug. 27, 2024. Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. will report earnings results for its third quarter fiscal 2024 ended June 30, 2024, on Tuesday, Aug. 13, 2024, before market open. The company will host a conference call to discuss its results with details the same day at 8:00 am Eastern Time.
Via Benzinga · August 6, 2024
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter fiscal 2024 ended June 30, 2024, on Tuesday, August 13, 2024, prior to market open.
By Organigram Holdings Inc. · Via Business Wire · August 6, 2024
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal at British American Tobacco plc (BAT).
By Organigram Holdings Inc. · Via Business Wire · July 29, 2024
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has completed an early partial funding of its final third tranche investment into Phylos Bioscience Inc. (“Phylos”), a U.S. cannabis genetics company and provider of production ready seeds, with the remaining portion of the final tranche to be funded upon completion of the newly expanded final milestone.
By Organigram Holdings Inc. · Via Business Wire · July 24, 2024
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) announced on Tuesday a strategic investment aimed at expanding its presence within the burgeoning European cannabis market. The Toronto-based company will utilize proceeds from its Jupiter strategic investment pool and invest €14 million ($15 million) initially. The sum includes €11.5 million via an unsecured convertible note and €2.5 million to purchase equity interests from existing Sanity Group founders and shareholders providing Organigram with a minority stake in Berlin-based cannabis company Sanity Group GmbH. Concurrent with the investment, Organigram and Sanity Group have entered into a new supply agreement to include significantly higher volumes and the intention to work together on the commercialization of Organigram's brands and intellectual property in Germany.
Via Benzinga · June 25, 2024
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce its first significant strategic investment aimed at expanding its presence in the European cannabis market. Using proceeds from its Jupiter strategic investment pool, the Company has agreed to invest €14 million (~ C$21 million) initially comprised of €11.5 million via an unsecured convertible note and €2.5 million to purchase equity interests from existing Sanity Group founders and shareholders providing the Company with a minority stake in Berlin-based cannabis company Sanity Group GmbH (“Sanity” or “Sanity Group”). In addition, the Company may advance another €3 million (~ C$4.5 million) as a second tranche of the unsecured convertible note for future opportunities to be pursued by Sanity subject to the satisfaction of certain conditions.
By Organigram Holdings Inc. · Via Business Wire · June 25, 2024
Germany's recent legislative push in the cannabis sector marks a significant turning point not only for the country but also for the European cannabis landscape. Europe has become more open-minded about medical and recreational marijuana over the recent years which is why the growing number of the North American cannabis operators that opted to venture into the new market doesn't come as a surprise. On Tuesday, Toronto-based cannabis giant Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) announced its second international medical cannabis customer in the UK, Avida Medical, a full-service medical cannabis and specials medicines manufacturing business.In the meantime, this week, Canadian cannabis brand Ghost Drops, announced an exclusive partnership with SOMAÍ Group, an international cannabinoid biopharma company with distribution channels.
Via Benzinga · May 28, 2024